Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: Amputation is still a viable option for musculoskeletal tumors that are multi-compartmental, adjacent to neurovascular structures, and involving pathological fractures. Complications such as poor surgical margins, local recurrence and infection after limb salvage surgery are also indications for secondary amputation. An effective hemostatic technique is vital for preventing complications of massive blood loss and prolonged operative time. The use of LigaSure™ in the field of musculoskeletal oncology has not been well documented.
Patients And Methods: This retrospective study included 27 patients with musculoskeletal tumor who underwent amputation using either LigaSure™ system (n=12) or traditional hemostatic technique (n=15) from 1999 to 2020. The purpose of this study was to evaluate the effect of LigaSure™ in terms of intra-operative blood loss, blood transfusion rates, and duration of surgery.
Results: The use of LigaSure™ resulted in a significant decrease in intraoperative blood loss (p=0.027) and blood transfusion rates (p=0.020). There was no significant difference for the duration of surgery between the two groups (p=0.634).
Conclusion: The LigaSure™ system can potentially improve clinical outcomes in patients with musculoskeletal tumor undergoing amputation surgeries. The LigaSure™ system is a safe and effective hemostatic tool for musculoskeletal tumor amputation surgeries.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.16374 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-Line Aumolertinib in -Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up.
Oncol Res
September 2025
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases.
Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint.
IgG4-Related Disease Inflamatory Pseudotumor Affecting the Sternoclavicular Joint: A Clinical Challenge.
Case Reports Immunol
August 2025
General Hospital Dr. César Cals, Avenida do Imperador, 545, Centro, Fortaleza, Ceará, Brazil.
IgG4-related disease (IgG4-RD) is a rare, progressive, and immune-mediated fibroinflammatory disorder that primarily affects middle-aged men and is more prevalent in Asian populations. Although extensively studied, its pathophysiology remains incompletely understood. This case report describes a 44-year-old male presenting with multiple abscesses and progressive inflammatory symptoms, ultimately diagnosed with IgG4-RD with musculoskeletal involvement.
View Article and Find Full Text PDFMRI versus radiography as eligibility screening tool for knee osteoarthritis clinical trials: Data from the osteoarthritis initiative.
Semin Arthritis Rheum
August 2025
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. Electronic address:
Objective: To estimate the prevalence of knee structural pathologies that may warrant exclusion from disease-modifying osteoarthritis drug (DMOAD) trials, based on MRI versus radiography, among participants who would otherwise be considered eligible for enrollment based on commonly used radiographic inclusionary criteria.
Methods: We selected participants from the baseline visit of the Osteoarthritis Initiative that met radiographic structural and clinical eligibility criteria for a DMOAD clinical trial: Radiographic OA (Kellgren-Lawrence grade 2 or 3 with medial minimum joint space width ≥ 1.5 mm); and WOMAC knee pain score between 8 and 18 (0-20 scale).
Preoperative intensity-modulated radiation therapy in lower extremity soft tissue sarcomas with and without dose avoidance of uninvolved skin/subcutaneous tissue.
Cancer
September 2025
Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
Background: The objective of this study was to evaluate whether dosimetric sparing of uninvolved normal tissues, including skin/subcutaneous flaps, affects acute and late toxicities in preoperative image-guided intensity-modulated radiation therapy (IG-IMRT) for lower extremity soft tissue sarcomas (LE-STS).
Methods: Patients with LE-STS from a phase 2 preoperative IG-IMRT trial (flap-sparing-IMRT, 2005-2009) and a prospectively maintained institutional database (standard-IMRT, 2005-2020) were propensity matched by age, sex, tumor size, grade, location, wound closure, and interval from IG-IMRT to surgery; all received 50 Gy in 25 fractions preoperatively. The primary outcome was major wound complication (MWC).
Clinical and radiological outcomes of bioactive glass in the treatment of benign bone tumors: a retrospective study of 64 cases.
Ulus Travma Acil Cerrahi Derg
September 2025
Departmant of Orthopedics and Traumatology, Istanbul University Istanbul Faculty of Medicine, Istanbul-Türkiye.
Background: Benign and benign-aggressive bone tumors, though non-metastatic, may require surgical intervention due to pain, fracture risk, or functional impairment. In many cases, bone grafting may be required in benign or benign-aggressive bone tumors. Although autografts remain the gold standard, they present disadvantages, especially in pediatric patients.
View Article and Find Full Text PDF